Saudi Arabia Antibody Drug Conjugates Market Size & Outlook
Saudi Arabia antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Saudi Arabia antibody drug conjugates market highlights
- The Saudi Arabia antibody drug conjugates market generated a revenue of USD 10.9 million in 2021 and is expected to reach USD 62.9 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 21.5% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 10.9 million |
| Market revenue in 2030 | USD 62.9 million |
| Growth rate | 21.5% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.2% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 95.7 million by 2030.
Breast cancer was the largest segment with a revenue share of 55.05% in 2021. Horizon Databook has segmented the Saudi Arabia antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Breast cancer is highly prevalent in Saudi Arabia, at a rate of 21.8%, as reported in the US National Library of Medicine. Saudi Arabia provides free healthcare services to citizens given its high oil revenue.
Furthermore, pharmaceutical companies such as Roche are reported to have been working actively with the Government of Saudi Arabia and National Cancer Associations to help educate healthcare workers on examination & diagnosis.
Moreover, Roche has partnered with the Ministry of Health in Saudi Arabia to raise awareness about breast cancer in terms of increasing early detection & subsequently reducing implications & burden of late diagnosis. These factors are expected to contribute to development of ADCs over the coming years.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia antibody drug conjugates market size, by application, 2018-2030 (US$M)
Saudi Arabia Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
